, AKRO
--/--/-- --:--:-- Back to news
| Date: | --/--/-- --:--:-- |
| Event Id: | E5DOH45SG |
| Action Type: | ACQUISITION |
| Action Status: | COMPLETED |
| Acquirer Symbol: | |
| Target Symbol: | AKRO |
| Updated: | --/--/-- --:--:-- |
| Purchase Price Per Share: | 54 |
| Price Per Share Currency: | USD |
| News References: | https://www.globenewswire.com/news-release/2025/12/09/3202389/0/en/Novo-Nordisk-has-completed-its-acquisition-of-Akero-Therapeutics.html |
Action Notes
Novo Nordisk today announced that it has entered into a definitive agreement to acquire Akero Therapeutics, Inc. Novo Nordisk to acquire Akero Therapeutics for 54 USD per share (4.7 billion USD) in cash at closing with a contingent value right (CVR) of 6 USD per share (0.5 billion USD) The transaction has been unanimously approved by Akero's Board of Directors and is expected to close around the turn of the year, upon satisfaction of customary closing conditions including approvals by regulatory authorities. The Akero Therapeutics special shareholder meeting to vote on the transaction will be held on 12/02.